SEER
Seer, Inc.
Biotechnology · Healthcare · United States
1.91
close · 2026-09-14
value
91
cheaper than peers91
quality
40
stronger fundamentals40
ranked against
Biotechnology (commercial)
value
quality
159 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.47× | 97 |
| EV to EBITDA | 0.32× | 84 |
| price to sales | 7.63× | 64 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -26.4% | 68 |
| debt to equity | 9.9% | 61 |
| operating margin | -542.9% | 33 |
| revenue growth | -23.4% | 26 |
4 of 4 measures available
Facts
| market cap | $106M |
| free cash flow | -$26.8M |
| employees | 124 |
| first trade | 2020-12-04 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.28 | -1.39 | -1.35 | -1.49 |
| free cash flow | -$46.2M | -$49.7M | -$66.4M | -$71.0M |
| net income | -$73.6M | -$86.6M | -$86.3M | -$93.0M |
| revenue | $16.1M | $13.9M | $15.2M | $14.7M |